Old Web
English
Sign In
Acemap
>
authorDetail
>
Lori Cox
Lori Cox
Pfizer
Internal medicine
Gastroenterology
Placebo
Medicine
Adverse effect
3
Papers
19
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
2021
Journal of The American Academy of Dermatology
Brett A. King
Emma Guttman-Yassky
Elena Peeva
Anindita Banerjee
Rodney Sinclair
Ana B. Pavel
Linda Zhu
Lori Cox
Brittany G. Craiglow
Linda H. Chen
Christopher Banfield
Karen Page
Weidong Zhang
Michael Vincent
Show All
Source
Cite
Save
Citations (4)
Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.
2020
Clinical pharmacology in drug development
Srividya Neelakantan
Barry Oemar
Kristen Johnson
Natalie Rath
Mikhail Salganik
Gabe Berman
Kathleen Pelletier
Lori Cox
Karen Page
Dean Messing
Sanela Tarabar
Show All
Source
Cite
Save
Citations (0)
Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor in Patients with Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
2020
Arthritis & Rheumatism
Michael F. Robinson
Nemanja Damjanov
Bojana Stamenkovic
Goran Radunovic
Alan J. Kivitz
Lori Cox
Zorayr Manukyan
Christopher Banfield
Michael Saunders
Deepa Chandra
Michael S. Vincent
Jessica Y. Mancuso
Elena Peeva
Jean Beebe
Show All
Source
Cite
Save
Citations (15)
1